Revive Therapeutics (FRA:31R) Moat Score: 3/10 (As of Jul. 11, 2026)


What is Revive Therapeutics Moat Score?

Revive Therapeutics FRA:31R Moat Score is 3 as of Jul. 11, 2026. The stock has 2 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Revive Therapeutics ranks better than 86.03% on this metric.

Revive Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Revive Therapeutics has No Moat: Revive Therapeutics Ltd has limited market presence and lacks significant intellectual property or regulatory advantages. The company does not exhibit strong brand strength or customer loyalty, and its competitive advantages are transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Revive Therapeutics might have No Moat - Very weak/transient advantages.

Revive Therapeutics  (FRA:31R) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Revive Therapeutics Moat Score Related Terms

FRA:31R vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revive Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Revive Therapeutics (FRA:31R) has a Moat Score of 3 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Revive Therapeutics ranks #144 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Revive Therapeutics' Moat Score too high?
Revive Therapeutics' current Moat Score is 3. Based on the distribution chart, Revive Therapeutics ranks #144 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Revive Therapeutics' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Revive Therapeutics ranks #144 out of 1031 companies for Moat Score. This places Revive Therapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Revive Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (FRA:31R) has a current Moat Score of 3. The current Moat Score is 3. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Revive Therapeutics (FRA:31R), the current Moat Score is 3 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revive Therapeutics Business Description

Other Exchanges RVVTF:USARVV:Canada
Address 82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.